公开(公告)号：US20250009876A1

公开(公告)日：2025-01-09

申请号：US18581446

申请日：2024-02-20

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina LOOMIS ,  Leon F. GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katherine Lee HENDRIX ,  Ethan W. OJALA ,  Pei FAN ,  Jeffrey T.L. SMITH ,  John A. LATHAM ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Vanessa Lisbeth RUBIN ,  Jens J. BILLGREN

IPC: A61K39/395 ,  A61K38/00 ,  A61K38/17 ,  A61K38/22 ,  A61K39/00 ,  A61K48/00 ,  A61P9/08 ,  A61P25/06 ,  C07K14/47 ,  C07K14/575 ,  C07K14/705 ,  C07K14/72 ,  C07K16/18 ,  C07K16/26 ,  C07K16/28 ,  C07K16/42 ,  C12N5/07 ,  C12N15/09 ,  C12N15/63 ,  G01N33/68

Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

公开(公告)号：US20210324068A1

公开(公告)日：2021-10-21

申请号：US16953443

申请日：2020-11-20

Applicant: H. LUNDBECK A/S

Inventor： Adisa KUBURAS ,  Bianca MASON ,  Levi P. SOWERS ,  Andrew F. RUSSO ,  Maria-Cristina LOOMIS ,  Leon F. GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katherine Lee HENDRIX ,  Ethan W. OJALA ,  Pei FAN ,  Jeffrey T.L. SMITH ,  John A. LATHAM ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Vanessa Lisbeth RUBIN ,  Jens J. BILLGREN

IPC: C07K16/26 ,  A61K39/395

Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

公开(公告)号：US20220289836A1

公开(公告)日：2022-09-15

申请号：US17553280

申请日：2021-12-16

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina LOOMIS ,  Leon F. GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katherine Lee HENDRIX ,  Ethan W. OJALA ,  Pei FAN ,  Jeffrey T.L. SMITH ,  John A. LATHAM ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Vanessa Lisbeth RUBIN ,  Jens J. BILLGREN

IPC: C07K16/26 ,  A61K39/395

Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.

公开(公告)号：US20210179688A1

公开(公告)日：2021-06-17

申请号：US17122243

申请日：2020-12-15

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina LOOMIS ,  Leon F. GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katherine Lee HENDRIX ,  Ethan W. OJALA ,  Pei FAN ,  Jeffrey T.L. SMITH ,  John A. LATHAM ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Vanessa Lisbeth RUBIN ,  Jens J. BILLGREN

IPC: C07K14/705 ,  C12N15/09 ,  C12N15/63 ,  A61K39/395 ,  C07K16/28 ,  A61K38/17 ,  A61K38/22 ,  C07K14/47 ,  C07K14/72 ,  C07K16/18 ,  C12N5/07 ,  C07K16/26 ,  C07K16/42 ,  G01N33/68

Abstract: The present invention is directed to antibodies and antigen binding fragments thereof having binding specificity for PACAP. The antibodies and antigen binding fragments thereof comprise the sequences of the VH, VL, and CDR polypeptides described herein, and the polynucleotides encoding them. Antibodies and antigen binding fragments described herein bind to and/or compete for binding to the same linear or conformational epitope(s) on human PACAP as an anti-PACAP antibody. The invention contemplates conjugates of anti-PACAP antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. Methods of making said anti-PACAP antibodies and antigen binding fragments thereof are also contemplated. Other embodiments of the invention contemplate using anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, photophobia, mast cell degranulation, and/or neuronal activation, would be therapeutically beneficial.

公开(公告)号：US20210380676A1

公开(公告)日：2021-12-09

申请号：US17201424

申请日：2021-03-15

Applicant: H. LUNDBECK A/S ,  The University of Iowa Research Foundation

Inventor： Adisa KUBURAS ,  Bianca MASON ,  Levi P. SOWERS ,  Andrew F. RUSSO ,  Maria-Cristina LOOMIS ,  Leon F. GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katherine Lee HENDRIX ,  Ethan W. OJALA ,  Pei FAN ,  Jeffrey T.L. SMITH ,  John A. LATHAM ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Vanessa Lisbeth RUBIN ,  Jens J. BILLGREN

IPC: C07K16/26 ,  A61K39/395

Abstract: This invention relates to methods of screening for anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof, for potential use in treating or preventing PACAP-associated photophobia or light aversion, and therapeutic compositions containing and methods of using anti-PACAP antibodies, or anti-PACAP receptor antibodies, and antigen binding fragments thereof.

公开(公告)号：US20210277106A1

公开(公告)日：2021-09-09

申请号：US17202790

申请日：2021-03-16

Applicant: H. LUNDBECK A/S

Inventor： Maria-Cristina LOOMIS ,  Leon F. GARCIA-MARTINEZ ,  Benjamin H. DUTZAR ,  Daniel S. ALLISON ,  Katherine Lee HENDRIX ,  Ethan W. OJALA ,  Pei FAN ,  Jeffrey T.L. SMITH ,  John A. LATHAM ,  Charlie KARASEK ,  Jenny MULLIGAN ,  Michelle SCALLEY-KIM ,  Erica STEWART ,  Vanessa Lisbeth RUBIN ,  Jens J. BILLGREN

IPC: C07K16/26 ,  A61K39/395

Abstract: The present invention is directed to antagonistic antibodies and antigen binding fragments thereof having binding specificity for PACAP. These antibodies inhibit, block or neutralize at least one biological effect associated with PACAP, e.g., vasodilation. In exemplary embodiments these antibodies and antigen binding fragments thereof may comprise specific VH, VL, and CDR polypeptides described herein. In some embodiments these antibodies and antigen binding fragments thereof bind to and/or compete for binding to specific epitope(s) on human PACAP. The invention is further directed to using these antagonistic anti-PACAP antibodies, and binding fragments thereof, for the diagnosis, assessment, and treatment of diseases and disorders associated with PACAP and conditions where antagonism of PACAP-related activities, such as vasodilation, mast cell degranulation, and/or neuronal activation, are therapeutically beneficial, e.g., headache and migraine indications.